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ABSTRACT 
 
Vitamin D, more specifically 1,25-dihydroxyvitamin D3, has received increasing 
attention over the past several years for its widespread effects on the genome. 
This study hypothesized that 1,25-dihydroxyvitamin D3 decreases proliferation 
and induces glia acitic fibrillary protein (GFAP), a marker for differentiation, 
mRNA in primary rat cortical astrocytes. To test the hypothesis, the presence of 
the vitamin D receptor in primary rat cortical astrocyte cells was confirmed using 
RT-PCR, western blot analysis, and immunofluorescent labeling. The presence 
of 1α-hydroxylase, the enzyme responsible for converting circulating 
25-hydroxyvitamin D3 to biologically active 1,25-dihydroxyvitamin D3, was also 
investigated. Messenger RNA levels for 1α-hydroxylase fell below the detection 
range for RT-PCR, and western blotting was negative for 1α-hydroxylase; 
however, immunofluorescent labeling was positive for the enzyme. The induction 
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of 24-hydroxylase mRNA, which codes for an enzyme that is up-regulated in 
response to 1,25-dihydroxyvitamin D3 in numerous cell types, was measured. 
Treating astrocyte cells with different levels of 1,25-dihydroxyvitamin D3 for 8 
hours resulted in a dose-dependent downstream effect, up-regulating 
24-hydroxylase mRNA by 40-890 fold (p<.05). To test the specific hypothesis 
regarding proliferation and differentiation, cells were treated with 1x10-6M 
1,25-dihydroxyvitamin D3 for 24 hours. A significant decrease in 3H-thymidine 
incorporation into astrocyte cells was observed (p<.05) suggesting that 
1,25-dihydroxyvitamin D3 regulates cell proliferation. Additionally, GFAP mRNA 
was significantly decreased when cells were treated with 1x10-10M 
1,25-dihydroxyvitamin D3 (p<.05) for 8 hours, but no dose dependent response 
was observed. Results suggest that the biologically active form of vitamin D, 
1,25-dihydroxyvitamin D3, significantly reduced cell proliferation at concentrations 
of 1x10-6M and down-regulated GFAP mRNA at 1x10-10M in primary rat cortical 
astrocyte cells in vitro. Understanding the effects of 1,25-dihydroxyvitamin D3 on 
cells of the central nervous system is an important step towards understanding 
the hormone’s effects under both normal and pathological conditions in the brain. 
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INTRODUCTION 
 
  Vitamin D has long been associated with calcium homeostasis and bone 
formation. The vitamin D receptor (VDR), however, is not limited only to cells 
involved in bone formation. Rather, evidence demonstrates that nearly all 
mammalian cell types have VDRs1. The ubiquitous presence of the VDR 
prompted some scientists to explore other possible roles of vitamin D beyond 
calcium homeostasis and bone formation2. The possible effects of vitamin D in 
the brain are intriguing, and not only because proper brain function centers 
around calcium homeostasis. 
 Vitamin D ultimately forms from the cholesterol precursor 
7-dehydrocholesterol. When 7-dehydrocholesterol, provitamin D3, is exposed to 
UV radiation (290-315nm), one of the rings opens forming previtamin D33,4. Thus, 
Vitamin D is considered a secosteroid, a steroid with a “cut” ring. Previtamin D3 
converts to vitamin D3 by thermal isomerization. Vitamin D3, however, is not 
biologically active until it undergoes two successive hydroxylation reactions. The 
first hydroxylation reaction occurs in the liver where the enzyme 25-hydroxylase 
(CYP2R1) converts vitamin D3 into 25-hydroxyvitamin D3 [25(OH)D3], also known 
as calcidiol. The second hydroxylation occurs throughout the nephron of the 
kidney where the 1α-hydroxylase enzyme (CYP27B1) converts 25(OH)D3 into 
biologically active 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], also known as 
calcitriol; see fig. 15–7. 
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Figure 1. Vitamin D Formation and Metabolism. In the skin, 7-dehydrocholesterol (provitamin D) 
exposed to UVB radiation converts to previtamin D. Previtamin D isomerizes into vitamin D3. 
Vitamin D3 may also be absorbed from dietary sources. In vivo, vitamin D3 undergoes two 
successive hydroxylation reactions; first in the liver where it is 25-hydroxylated and then in the 
kidney where it is 1α-hydroxylated forming active 1,25(OH)2D3. The presence of the 
1α-hydroxylase (CYP27B1) in microglia, neurons, and astrocytes of the brain would suggest that 
circulating 25(OH)2D3 converts to the bioactive 1,25(OH)2D3 in the brain. Scientists have 
previously demonstrated that microglia produce CYP27B1 in vitro. The arrows indicate 
conversion of 7-Dehydrocholesterol to 25-hydroxyvitamin D3 and the activation of 25(OH)D3 to 
1,25(OH)2D3. The dashed arrow indicates the first step in deactivation of 1,25(OH)2D3 by 
24-hydroxylase (CYP24A1), ultimately forming calcitroic acid for excretion. 
 
 Since at least 1979 scientists suspected that tissues other than the kidney 
also produced some enzyme that could convert 25(OH)D3 to 1,25(OH)2D38,9. 
Until the turn of the century, most evidence for extra-renal activation of 25(OH)D3 
was based on enzymatic studies and mRNA measurements10. In 2001, Zhender 
et al. found that the 1α-hydroxylase enzyme was present in extra-renal tissues 
including the cerebellum and cerebral cortex of the brain5. 1α-hydroxylase 
presence in the brain validated previous authors opinions that the enzyme in their 
northern blot analysis and enzyme activity studies, which demonstrated strong 
activation of 25(OH)D3 locally in the brain, was indeed 1α-hydroxylase5,10. 
Additional studies demonstrated that humans also express the 1α-hydroxylase 
enzyme in both neurons and glia throughout the brain with remarkable similarity 
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to patterns seen in the brains of rats11. The finding that the brain can locally 
activate 25(OH)D3 suggested that vitamin D, perhaps more appropriately called a 
hormone than a vitamin, may have autocrine and paracrine functions in the 
brain11. 
 The presence of the 1α-hydroxylase and its ability to locally activate 
25(OH)D3 mean little without a receptor to bind 1,25(OH)2D3. Studies on both 
developing and adult rats demonstrated that cells in the central nervous system 
(CNS) have a VDR12. Under the confocal microscopy, stained astrocytes isolated 
from rat hippocampus allowed researchers to better identify the presence of the 
VDR. In addition, scientists have since demonstrated the presence of the VDR in 
human astrocytes, which like the distribution of 1α-hydroxylase, also showed 
remarkable similarity to VDR localization in the brains of rats11. 
 Even before reports about the production of 1α-hydroxylase locally or the 
presence of the VDR in the brain, scientists speculated that the brain was a 
target of 1,25(OH)2D3. Vitamin D metabolites, both 25(OH)D3 and 1,25(OH)2D3 
had already been shown to cross the blood brain barrier in rats, but the question 
remained as to whether cells were using 1,25(OH)2D313. Autoradiograms in rats 
fed a vitamin D deficient diet and then injected with 3H-1,25(OH)2D3 showed 
3H-1,25(OH)2D3 was taken up into neuronal cells of the forebrain12. Questions 
remained about what function the 1,25(OH)2D3 performed once it was inside the 
cells of the CNS.  
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 1,25(OH)2D3 influences most cells primarily through the nuclear vitamin D 
receptor (VDR). The VDR binds to its ligand, 1,25(OH)2D3, and forms a 
hetero-dimer with one of three retinoid X receptors (RXRs) resulting in a 
VDR/RXR complex. The complex translocates to the nuclear DNA and binds to 
specific areas with a vitamin D response element (VDRE). Once bound to a 
response element the complex may up-regulate or down-regulate genes.  
 The genomic effect may be observed when 1,25(OH)2D3 up-regulates the 
24-hydroxylase gene (CYP24A1). 1,25(OH)2D3 induces 24-hydroxylase mRNA 
by up to 1,000 fold14. 24-hydroxylase provides a negative feedback that also 
converts 1,25(OH)2D3 into calcitroic acid. When the concentration of 1,25(OH)2D3 
elevates, the CYP24A1 gene is up-regulated. 24-hydroxylase mRNA levels 
increase which ultimately leads to an increase in the 24-hydroxylase enzyme. 
The enzymatic action of 24-hydroxylase renders 1,25(OH)2D3 inactive as water 
soluble calcitroic acid. Calcitroic acid can then be excreted through the urine6,7. 
The result is that high concentrations of 1,25(OH)2D3 are decreased which in turn 
reduces the number of VDR/RXR hetero-dimers that can bind to the CYP24A1 
response element, hence the negative feedback of 24-hydroxylase. By inducing 
the CYP24A1 gene, cells tightly regulate levels of 1,25(OH)2D3. 1,25(OH)2D3 
affects other genes in addition to CYP24A1, either up-regulating or 
down-regulating genes. 
 Astrocytes, the most common cell type in the CNS, respond to 
1,25(OH)2D3 like other cells by substantially up-regulating CYP24A1.16 
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Traditionally thought of as the “glue” of the brain, astrocytes help form the blood 
brain barrier. New imagining and experimental techniques helped scientists 
discover that some astrocytes span the width of the brain forming discrete 
compartments renewing interest in astrocytes beyond their classical 
functions17,18. Astrocytes regulate synaptic transmission of neurons by releasing 
neurotransmitters such as glutamate and other regulatory molecules such as 
adenosine tri-phosphate (ATP). Astrocytes can also affect extra-synaptic regions 
of neurons by regulating extracellular environments. Glial networks, called 
astrocytic syncytia, even propagate signals of their own in the form of calcium 
waves17. 1,25(OH)2D3 may be particularly interesting to study in astrocytes and 
not exclusively for its role in inducing CYP24A1. 
 Scientists have discovered that 1,25(OH)2D3 affects other  genes in 
addition to CYP24A1, which may also hold true in astrocytes. For example, the 
relationship between 1,25(OH)2D3 and calcium channels appears strong. 
1,25(OH)2D3 down-regulates the L-type voltage gated calcium channels, 
LVSCC-A1C and LVSCC-A1D19. But 1,25(OH)2D3 also up-regulates such genes 
as nerve growth factor (NGF) and glial derived neurotrophic factor (GDNF); see 
table 1. For some genes, such as connexin 43 (Gja1) the relationship is less 
substantiated and only observed in a single study and single cell type not yet 
astrocytes20. These examples represent only a fraction of the possible gene 
targets that 1,25(OH)2D3 may affect in astrocytes. 
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 Reports of the number of genes regulated by 1,25(OH)2D3 range from 200 
to over 2,00021. 291 genes have been reported to be affected by vitamin D 
supplementation in humans22. Many of the genes that 1,25(OH)2D3 influences 
play a role in cell growth and proliferation. Vitamin D has been shown to have 
antiproliferative effects in C6 glioma cell lines among other cancers, and vitamin 
D deficiency may increase risk in other cancers such as prostate cancer23–25. 
1,25(OH)2D3 blocks the G0/G1 to S transition of the cell cycle. Up-regulation of 
four genes are particularly well established in the literature in regards to this 
block: CDK inhibitors p21 and p27, cyclin C, and PPAR gamma1. Interestingly, 
some cancer cell lines are resistant to the effects of 1,25(OH)2D3 antiproliferative 
effects. For example the Glioblastoma multiform (GBM) cell line does not 
respond to 1,25(OH)2D3 treatment in vitro26. Control over cell proliferation has 
obvious implications not only in cancer but perhaps also in normal cells.  
 The role of 1,25(OH)2D3 in the control of cell proliferation may be 
important in how the central nervous system responds to injury. After any type of 
damage, astrocytes clear cellular debris, secrete trophic factors, undergo cellular 
changes (increase in GFAP), and proliferate to form scars that wall off the injury 
site. Since astrocytes secrete and regulate much of the CNS cellular 
environment, 1,25(OH)2D3 may play a large role in inducing genes that contribute 
to astrocyte migration, proliferation, inflammation, and neuronal growth factors; 
specifically during the formation of glial scars following injury17.  
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Table 1. Widespread Effects of 1,25(OH)2D3 on the CNS and PNS 
1627282930313233343536373832394041424344454647484950512452535455 
a  Abbreviations: 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; ChAT, choline acetyl transferase; EAE, 
experimental autoimmune encephalomyelitis, γ-GT, γ-glutamyl transpeptidase; GDNF, glial cell 
line derived neurotrophic factor; GSH, glutathione; iNOS, inducible nitric oxide synthase; IL-4, 
interleukin 4; LIF, leukemia inhibitory factor; L-VSCC, L-type voltage sensitive calcium channel; 
M-CSF, macrophage colony-stimulating factor; NGF, nerve growth factor; NT-3, neurotrophin 3; 
NT-4, neurotrophin 4; 6-OHDA, 6-hydroxydopamine; p75, low-affinity NGF receptor; TGF-β, 
transforming growth factor β; TH, tyrosine hydroxylase; TNF-α, tumor necrosis factor α; VDR, 
vitamin D receptor.  
b Widespread effects of the hormone 1,25(OH)2D3, on the CNS and PNS under normal or 
pathological conditions. The up arrows indicate positive regulatory effects and the down arrows 
negative regulatory effects. Table amended from Garcion et al., 2002.  
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 To summarize, vitamin D metabolites pass the blood brain barrier where if 
not already in the active form; 25(OH)D3 may be activated locally by 
1α-hydroxylase and bind to the VDR receptor56. VDR-RXR hertero-dimers form 
and may bind to VDREs to induce genes. This system has been demonstrated in 
astrocytes by the induction of the 24-hydroxylase (CYP24A1) gene. 
Understanding which genes are induced by 1,25(OH)2D3 in different cell types 
may help elucidate mechanism behind pathologies or normal cellular processes 
such as recovery from injury; an interesting example is the case of glial scar 
formation that follows trauma. The effects of 1,25(OH)2D3 on gene products in 
cells of the brain, such as astrocytes, deserve further exploration. 
 
AIMS 
 
 Vitamin D is known to help regulate calcium levels in the blood and some 
tissues, but relatively little is known regarding vitamin D’s effects in the brain. 
Astrocytes on the other hand, have long been appreciated for their supportive 
role in the brain. Insights suggest astrocytes play an important role in responding 
to injury in the brain. Studies in various cell types demonstrate that 1,25(OH)2D3 
affects cell proliferation and differentiation, which for astrocytes, would have 
implications in formation of glial scars. This study hypothesized that 1,25(OH)2D3 
treatment would reduce astrocyte cell proliferation and up-regulate GFAP mRNA. 
The study had two aims to test the hypothesis:  
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 Aim 1. Confirm that primary rat astrocytes have a functional VDR, have 
the enzymatic machinery to activate 25(OH)D3 locally, and induce 
24-hydroxylase at the gene level. 
 Aim 2. Determine the effect of 1,25(OH)2D3 treatment on 3H-thymidine 
incorporation and GFAP mRNA levels compared to control. 
Ultimately, the goal was to explore if the hormone 1,25(OH)2D3 affects 
proliferation or differentiation in primary rat astrocyte cells in vitro, which may 
play a role in astrocyte differentiation and response to injury. 
 
MATERIALS AND METHODS 
 
Cell Culture 
  
 To culture primary rat cortical astrocytes; P2 rats cortices were isolated in 
accordance with the Boston University IACUC guidelines57. Pups were separated 
from the mother and immediately decapitated. The skin was removed from the 
skull. The skull was opened to expose the hemispheres of the brain. The brain 
was removed with the cerebellum and immediately placed with the hemispheres 
submerged in dissection medium (Gibco, 14025-134) on ice. The meninges, 
cerebellum, hippocampus, and surrounding tissue were removed. Lastly the 
olfactory bulbs were removed so that only the cortex remained. The cortex was 
transferred into clean dissection medium; see fig. 2. 
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Figure 2. Dissection of the P2 Rat Cortex. (a) The skull of the P2 rat was held by the nose while 
the skin was removed. The skull was opened, and the brain was removed with a spatula. The 
dotted line shows the midline cut through the skull. (b) The brain was cut in half along the midline 
yielding the olfactory bulb, cerebral hemisphere, and cerebellum. The dotted line indicates the cut 
to remove the cerebellum. (c) From a dorsal view of one cerebral hemisphere the dotted line 
indicates the cut to remove the olfactory bulb. (d) The arrows indicate where to dissect out the 
hippocampus to yield only cortical tissue. Only the cerebral cortex remained after removing the 
basal ganglia. Figure adapted from ChenYing, 2007. 
 
 The cortices were washed three times with cold dissection medium and 
cut into small pieces. Trypsin (Sigma, D5025) and DNAseI (Sigma, D5025) 
diluted in dissection medium at pH 7.5 was added to the homogenized cortices 
and mixed. After incubating for 15 min at 37°C the mixture was mechanically 
disassociated using a pipette and centrifuged at 1,000 rpm for 5 min. The 
supernatant was removed and shaking medium (Gibco, 11960-044) was added. 
The cells were mechanically disassociated again using a pipette and the mixture 
was allowed to settle for 20 min. The suspension was passed through a 70µm 
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nylon strainer (BD Falcon, 352350) and collected into a sterile tube. Additional 
shaking medium was added to the pellet and cells were mechanically 
disassociated again, allowed to settle, and strained into the same tube. The 
process was repeated so that the cortical tissue was filtered three times. The 
filtered cells were added to culture flasks previously treated with poly-D-lysine 
(Sigma-Aldrich, P0899). The cells were incubated at 37°C with 6.5% CO2. The 
shaking media was replaced every other day. 
 On the 10th and 17th day after dissecting, the cells were shaken overnight 
on an orbital shaker at 37°C and 230 rpm, to loosen microglia and 
oligodendrocytes for removal. Finally cells were passed and plated on 
poly-D-lysine coated Nuclon® (Thermo Scientific, 172958) culture dishes on day 
18. The cells were cultured at 37°C with 6.5% CO2. Culturing medium consisted 
of 78% DMEM (Sigma Aldrich, D7777), 20% FBS (HyClone, SH30088.03), 0.5% 
L-Glutamine (Gibco, 25030-016), and 0.5% Pen/Strep Amphotericin B (Lonza, 
17-745E) and was changed at most every third day. 
  
Immunofluorescent Imaging 
  
 Astrocytes were plated at ~15,000 cells/cm3 on slide cover slips, 
previously treated with poly-D-lysine, and cultured in a six well culture plate for 
four days. 24 hours before fixing, the cells were treated with 1,25(OH)2D3. On the 
day of imaging the media was removed, and the cells were rinsed three times 
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with room temperature PBS, phosphate-buffered saline, (Gibco, 7001144), pH 
7.4. The cells were submerged in 4.0% paraformaldehyde (Electron Microscopy 
Sciences, 157-4) in PBS for 30 min at room temperature. After fixing, the cells 
were rinsed once with PBS and three times with 30mM glycine (Fischer 
Scientific, BP381-1) in PBS for 5 min each time. Cells were incubated with 0.2% 
Triton X-100 (American BioAnalytical, AB2025) in PBS for 5 min. After washing a 
final time with PBS, cover slips were blocked in 10% goat serum (Gibco®, 
16210-064) for 1 hour at room temperature. Cells were incubated with different 
primary antibodies; GFAP (Santa Cruz Biotechnology, GA-5) to immunolabel 
astrocyte cells, anti-VDR (Santa Cruz Biotechnology, D-6) to label the VDR, 
anti-CYP27B1 (Millipore, ABN182) to label 1α-hydroxylase, or anti-Olig2 
(Millipore, AB9610) to label oligodendrocytes. All antibodies were diluted to 1:250 
in blocking solution and added to the cells for 45 min at 37°C. Cells were rinsed 
with 0.2% tween-20 (Santa Cruz Biotechnology, sc-29113) in blocking solution 
for 5 min. Relevant secondary antibodies were diluted to 1:500 in blocking 
solution and added collectively to cells for 45 min at room temperature. The 
secondary antibodies included; A21133, A21070, A21121 Alexa Fluor® (Life 
Technologies™). Cells were washed three times with 0.2% tween-20 in PBS for 5 
min and washed once with PBS. A final rinse with MilliQ water was used before 
mounting with Vectashield aqueous DAPI (Vector labs, H-1200). Immunolabeled 
cells were visualized using a Zeiss LSM-710 confocal microscope.  
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Cell Treatment 
 
 Crystaline 1,25(OH)2D3 (Hoffmann – La Roche, 21-5535) was added to 
100% ethanol and adjusted to a concentration of 1x10-3M. Concentration was 
confirmed using absorbance from a spectrophotometer and applying Beers Law 
with a maximum peak absorption at ~265 and an extinction coefficient of 18,400 
[maximum absorption = concentration / (wave length x path length x extinction 
coefficient)]. The stock solution was diluted in treatment medium, DMEM without 
FBS, to different concentrations; 1x10-6M, 1x10-8M, and 1x10-10M. Cells were 
treated for 8 to 24 hours with respective concentrations of 1,25(OH)2D3 before 
measuring for 3H-thymidine incorporation, lysing for western blot analysis, or 
extracting total RNA for RT-PCR experiments. 
 
3H-Thymidine Incorporation 
 
 Cells were passed into a 24 well plate so that they were 30% confluent the 
following day. Cells were incubated for 24 hours in media without FBS and 
treated with either vehicle control (100% ethanol) or 1,25(OH)2D3 at 1x10-6M, 
1x10-8M, and 1x10-10M. After 24 hours of treatment the media was removed and 
replaced with media without FBS containing 3H-thymidine (PerkinElmer, 
NET0227001). After incubating with 3H-thymidine for 3 hours the media was 
removed and the plate was placed on ice. The cells were rinsed 3 times with 
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PBS. 5.0% perchloric acid (Fisher Scientific, A229) was added to each well for 20 
min and then rinsed once with 5.0% perchloric acid. 350µl of fresh perchloric acid 
was added to each well and the plate was floated in a 70°C water bath for 30 
min. The 350µl of perchloric acid within each well was transferred into separate 
opaque tubes. 3.0mL of ScintiVerse™ BD cocktail (Fisher Scientific, SX18-4) 
was added to each tube. The tubes were placed in a microbeta trilux machine 
and the 
3H-thymidine analyzed using MicroBeta WIW software. 
  
Protein Extraction 
 
 Cells that had been cultured in 100mm plates were removed from the 
incubator after the cells had been treated with 1,25(OH)2D3 for 16 hours. The 
treatment media was removed. Cells within the plates were rinsed three times 
with cold PBS. After the final rinse, 750ml of Rippa Buffer, mammalian protein 
extraction reagent with halt protease inhibitor (Thermo Scientific, 78501 & 78410) 
was added to the culture plate. The plate was shaken for 10 min and the cell 
lysate was collected into a 1.5ml microcentrifuge tube. The lysate was 
centrifuged at 14,000 times gravity for 15 min. The supernatant was collected 
into a fresh 1.5ml microcentrifuge tube and the protein concentration was 
measured before storing at -20°C until the protein was needed for western blot 
analysis. 
  
 
15 
 
Protein Quantification 
 
 Protein concentration was determined using a Pierce BCA Protein Assay. 
A standard curve was created using a series of dilutions containing bovine serum 
albumin protein standards (Thermos Scientific, 23209) diluted in mammalian 
protein extraction reagent (Thermo Scientific, 78501). A BCA protein assay kit 
(Thermo Scientific, 23227) was used as a working reagent and 200µl per well 
was added to a 96 well plate. 25µl of protein solution was added to different wells 
in duplicate and shaken for 30 seconds. The plate was covered and incubated for 
30 min at 37°C. After the plate cooled, the absorbencies at 562nm were 
measured in an Epoch (Biotek) plate reader and analyzed using Gene 5.1.10 
software. 
  
Western Blot 
 
 A NuPAGE 4-12% Bis Tris gel (Life Technologies™, IM-8042) with 12, 
1.0mm-wells was prepped and placed in an electrophoresis transfer cell filled 
with 20x running buffer (Invitrogen, NP0002) diluted with de-ionized water. 500µl 
of antioxidant (Invitrogen, NP0005) was added to the running buffer. 
 Microcentrifuge tubes were prepared so that the contents could be loaded 
into the gel. 2.0µl of sample reducing agent (Invitrogen, NP0009), 5.0µl of LDS 
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sample buffer (Invitrogen, NP0007), and 30.0µg of extracted whole cell protein 
lysate were combined in each tube. Incubating the tubes in a 70°C water bath for 
10 min denatured the proteins. The sample mixtures were added to the middle 
wells and a reference ladders (Invitrogen, LC5925) were added to the wells on 
each side. The proteins were run through the gel for 35 to 55 min at 164V 
depending on the protein of interest; VDR or 1α-hydroxylase respectively. 
 After running the gel, the proteins were transferred to a Novex LC 2001 
Nitrocellulose 0.45µm membrane. The membrane was soaked in transfer buffer 
for 2 min before transferring. Transfer buffer was made from 10X stock (Fischer 
Science, T395 & BP381-1) diluted in 2X 100% methanol and de-ionized water. 
Filter paper, the gel, the nitrocellulose membrane, and filter paper, oriented 
respectively, were sandwiched between the two sponges of the western box 
clamps. The transfer buffer and the clamped membrane were added to the 
electrophoresis box and the gel was transferred to the membrane at 220mA for 
50 min. 
 During the transfer a 10x TBST solution was made: 20mM Tris (Fisher 
Scientific, T395-1), 1.5M NaCl (American Bio Analytical, AB13170), and 1% 
Tween-20 (Santa Cruz Biotechnology, sc-29113) adjusted to pH 7.6 with HCL 
(American Bio Analytical, AB06037). After transferring, the nitrocellulose 
membrane was placed in a blotting box and covered with 5.0% blocking solution, 
5.0mL powdered milk with 1x TBST. The membrane with blocking solution was 
shaken for 1 hour at room temperature. 1.0% blocking solution with primary 
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monoclonal anti-VDR antibody (Santa Cruz Biotechnology, sc-13133) or primary 
polyclonal anti-CYP27B1 antiserum (Millipore, ABN182) was added, at 1:1000 
dilution, to the membrane and shaken for 12 hours at 4°C. 
 The membrane was washed in TBST for 5 min three times before adding 
the appropriate secondary antibody (Santa Cruz Biotechnology, sc-2005) or 
(Millipore, AP182P) diluted at 1:5,000 or 1:10,000 respectively in 1% blocking 
solution. The membrane was shaken with the secondary antibody for 1 hour at 
room temperature. The secondary antibody solution was removed and the 
membrane washed three times with 1x TBST for 5 min each time. 
 ECL solution (Novex® ECL, WP20005) was added to the blotting box for 
10 min in the dark. The membrane was removed and excess ECL solution 
dripped off of the membrane. The membrane saturated with ECL solution was 
placed in a developing cassette with film (Amersham Hyperfilm™, 28906835) for 
8 min exposure time. The film was developed in a Konica Minolta (SRX-101A) 
medical film processor. 
 
Total RNA Extraction 
 
 Following exposure to 1,25(OH)2D3 cells were removed from the incubator 
and lysed using TRIzol® reagent (Invitrogen, 15596-018). Cell lysate was 
transferred into a 1.5mL microtube and incubated for 5 min at 25°C. 0.2mL of 
chloroform was added to the microtubes, agitated for 1 min, and incubated for 5 
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min at 25°C. After centrifuging samples at 12,000 times gravity for 10 min at 4°C 
the aqueous phase was transferred into fresh microtubes, and 0.5mL of isopropyl 
alcohol was added to the aqueous phase for 15 min at 25°C. The mixture was 
centrifuged at 12,000 times gravity for 10 min at 4°C. The supernatant was 
removed and the pellet washed with 1mL of 75% ethanol in nuclease-free H20 
(Ambion, AM9937). The mixture was centrifuged at 7,500 times gravity for 5 min 
at 4°C. The pellet was air dried for 5 min and dissolved in 0.1mL of nuclease-free 
H20. The total RNA was measured on a spectrophotometer, where 260nm 
absorption was compared to 280nm, to confirm purity levels above a ratio of 1.7 
(A260/A280). Total RNA was stored at 0°C. 
 
cDNA Synthesis 
 
 cDNA was made from total RNA using a High Capacity cDNA Reverse 
Transcription kit. (Applied Biosystems, 4368814). An equal amount of sample 
and Master Mix were centrifuged for 5 min at 7,500 times gravity at 4°C. 
Microtubes were loaded into a thermal cycler (Perkins/Elmer) for 10 min at 25°C, 
120 min at 37°C, 5 min at 85°C, and finally cooled to 4°C. cDNA was measured 
on a spectrophotometer for purity. The concentration of the cDNA was 
determined using the formula A260/0.027 = C(µg/ml), where the extinction 
coefficient for single-stranded DNA was 0.0270µg/ml . The cDNA was stored at 
0°C until used. 
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RT-PCR 
 
 A Taqman RT-PCR gene assay was used to analyze the fold induction of 
different gene products. 5.0uL of Roche Light Cycler 480 Master Mix was added 
each well of Hard-Shell 384-Well 480 PCR plate. 50ng of astrocyte cDNA was 
added to each well. 0.5uL of the LifeTechnologies primer/probe for VDR 
(Rn00690616_m1), CYP27B1 (Rn00587137_m1), CYP24A1 (Rn01423143_m1), 
and GFAP (Rn00566603_m1) were diluted with nuclease-free H20 and mixed so 
that once added to the wells total reaction volume per well was 10uL. All steps 
were carried out on ice. The plate was covered with an optical adhesive cover 
(Applied Biosystems, 4317236) and centrifuged for 5 min at 2,000 rpm to mix the 
contents. The plate was loaded into a Roche480 PCR machine and the data 
collected. The delta delta ct method, described by Livak, was used to determine 
the fold induction associated with each treatment58. LifeTechnologies 
primer/probe for the18s gene (Hs03003631_g1) was used as the internal control. 
 
RESULTS 
 
 The study hypothesized that 1,25(OH)2D3 treatment would reduce cell 
proliferation and up-regulate GFAP mRNA, a marker for differentiation, in primary 
rat cortical astrocytes. To determine whether 1,25(OH)2D3 affects cell 
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proliferation or differentiation preliminary work was required. First, a culture of 
enriched primary astrocyte cells was needed. After establishing a culture, 
presence of the VDR in the astrocyte cells was confirmed. Next, whether the 
cells produced the 1α-hydroxylase, which converts inactive 25(OH)D3 to active 
1,25(OH)2D3, was explored. Lastly, induction of CYP24A1 mRNA by 1,25(OH)2D3 
was demonstrated to confirm that 1,25(OH)2D3 exerted downstream effects. 
Specifically, CYP24A1 mRNA induction demonstrated that the cellular processes 
necessary to induce genes were intact in the cultured cells. After the 
aforementioned preliminary work, the study tested the specific hypothesis on cell 
proliferation and differentiation; specifically, 3H-thymidine incorporation and 
GFAP mRNA expression in vitro. 
 Immunolabeling for the type I astrocyte marker GFAP and the 
oligodendrocyte marker Olig2, along with nuclear staining with DAPI determined 
the constituents of the cell culture. These three markers allowed for a qualitative 
comparison between astrocyte cells, oligodendrocytes, and other cell types or 
precursor cells. The numbers of each cell in representative areas were counted 
and totaled; see fig. 3. 85-95% of the cultured cells labeled for type I astrocytes 
marker GFAP. The proportion of cells in the culture that that were GFAP positive 
fit the criteria of an astrocyte-enriched culture59. Ant-Olig2 antibodies labeled 
oligodendrocyte nuclei and represented less than 3.0% of cells. Other cell types 
or precursors that stained with DAPI but did not label with either anti-Olig2 or 
anti-GFAP were likely precursors, microglial cells, or type II astrocytes. 
  
 
21 
 
Figure 3. Astrocyte-Enriched Cell Culture. A representative stitched Z-stack demonstrated 
astrocytes in culture. 88 Nuclei were stained with DAPI (blue) giving the total number of cells in 
the culture. Astrocytes were labeled with anti-GFAP (green) and matched closely with all but 6-14 
cells in this section. Three of the cells not representing astrocytes labeled with the 
oligodendrocyte marker anti-Olig2 (magenta) nuclei. Type I astrocyte cells represented 85-95% of 
cells in the astrocyte culture. Other cell populations may have been precursors, microglia, or type 
II astrocytes. 
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 Western blot analysis, RT-PCR, and immunolabeling all demonstrated the 
presence of the VDR receptor. Western blot analysis with an anti-VDR antibody 
and HRP secondary showed positive identification of the 48 kD VDR protein 
compared to positive control Hela cells; see fig. 4. RT-PCR measured mRNA 
expression in both treated and untreated cells. Fold induction was measured by 
the delta delta ct method, and a t-test was used to compare the mean RQ 
Values; see fig. 5. An inverse relationship between treatment concentrations and 
fold induction was observed; however, no significance was observed (p=.098, 
p=.25, and p=.14) between treatment and controls. Lastly, visualization of a 
fluorescent secondary antibody localized the VDR receptor in astrocytes treated 
with vehicle control (100% ethanol) and 1x10-6M 1,25(OH)2D3. Translocation of 
the VDR from the cytoplasm to the nucleus was apparent after cells were treated 
with the VDR ligand, 1,25(OH)2D3; see fig. 11 and 12. 
  VC  VC  -10 -10   -8    -8     -6    -6     +     + 
 
Figure 4. Western Blot Analysis of Vitamin D Receptor (VDR). Primary rat cortical 
astrocyte whole cell lysate was identified using a 1:1000 dilution of anti-VDR 
monoclonal antibody (Santa Cruz Biotechnology, sc-13133) and 1:5000 secondary 
HRP conjugate (Santa Cruz Biotechnology, sc-2005). Vehicle control (VC) and various 
concentrations of 1,25(OH)2D3 treatments (1x10-10M through 1x10-6M) were positive for 
the 48 kD VDR protein compared to positive control (+) Hela cell lysate. 
 48 kD 
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Figure 5. Vitamin D Receptor (VDR) Induction by 1,25(OH)2D3. VDR mRNA in primary rat cortical 
astrocytes treated for 8 hours with increasing concentrations of 1,25(OH)2D3 was measured using 
RT-PCR. The fold induction is represented by the relative quantity (RQ) value relative to control. 
Error bars denote SEM. Induction was observed at a concentration of 1x10-10M, 1x10-8M, and 
1x10-6M, but failed to reach a level of significance; (p>0.05) 
 
 The presence of the CYP27B1 enzyme was measured in the astrocyte 
population. Western blot analysis, RT-PCR, and immunolabeling allowed for 
determination of the presence of CYP27B1. Western blot analysis with an 
anti-1α-hydroxylase antibody and HRP secondary antibody demonstrated that 
little to no 1α-hydroxylase was present in the whole cell protein lysates compared 
to positive control 1α-hydroxylase transfected LnCap cells and negative control 
LnCap cells; see fig. 6. Additionally, despite detecting the presence of the 18S 
control gene, RT-PCR did not detect mRNA for CYP27B1 within the detection 
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limit. Immunolabeling, however, revealed that 1α-hydroxylase was present within 
the astrocyte cells when cells were labeled with an anti-1α-hydroxylase antibody 
and a fluorescent secondary antibody; see fig. 13.  
   VC  VC  -10  -10   -8   -8    -6    -6     +     -  
 
Figure 6. Western Blot Analysis of 1α-Hydroxylase (CYP27B1). Primary rat cortical 
astrocyte whole cell lysate was labeled using a 1:1000 dilution of anti-CYP27B1 
polyclonal antiserum (Millipore, ABN182) and 1:10,000 secondary HRP conjugate 
(Millipore, AP182P). Vehicle control (VC) and various concentrations of 1,25(OH)2D3 
treatments (1x10-10M through 1x10-6M) showed no 53 kD 1α-hydroxylase compared to 
positive control (+) 1α-hydroxylase transfected LNCaP cell lysate and levels similar to 
negative control (-) LNCaP cell lysate. Uncharacterized bands were seen at 55 kD and 
98 kD. 
  
 The fold induction of a gene known to be induced by 1,25(OH)2D3 in other 
cell types, 24-hydroxylase, CYP24A1 was measured. A time course was run in 
triplicate and the data pooled to optimize treatment time for the treatment 
concentration experiments. When cells were treated with 1x10-6M 1,25(OH)2D3 
induction of CYP24A1 was greatest between 4 and 12 hours. The time course 
showed that 8 hours following treatment, CYP24A1 was induced by over 250 
fold; see fig 7.  
 58 kD 
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Figure 7. Time Course of 24-Hydroxylase (CYP24A1) Induction. Primary rat cortical astrocytes 
were treated for up to 25 hours with 1,25(OH)2D3. The fold induction of the CYP24A1 mRNA at 
various time points was measured in astrocytes treated with 1x10-6M 1,25(OH)2D3 using RT-PCR. 
The fold induction is represented by the relative quantity (RQ) value relative to control. Error bars 
denote SEM. The maximum induction was observed between 4 and 12 hours following treatment. 
 
 After establishing that CYP24A1 induction was greatest between 4 and 12 
hours of treatment, cells were treated for 8 hours with different concentrations of 
1,25(OH)2D3. RT-PCR measured CYP24A1 mRNA expression. The fold 
induction was measured by the delta delta ct method and a t-test was used to 
compare the mean RQ Values. 1,25(OH)2D3 significantly induced CYP24A1 
mRNA in a dose dependent manner when compared to control (p=.013, p<.0005, 
and p=.0005) respectively; see fig. 8. 
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Figure 8. 24-Hydroxylase (CYP24A1) Induction by 1,25(OH)2D3. CYP24A1 mRNA in primary rat 
cortical astrocyte cells treated for 8 hours with increasing concentrations of 1,25(OH)2D3 was 
measured using RT-PCR. The fold induction is represented by the relative quantity (RQ) value 
relative to control. Error bars denote SEM. The maximum induction was observed at a 
concentration of 1x10-8M. At 8 hours CYP24A1 mRNA was significantly* increased compared to 
vehicle control (VC) at each of the three concentrations (p=0.13, p<.0005, and p=.0005) 
respectively. 
 
 After confirming that the cultured astrocytes had a VDR receptor and 
responded to 1,25(OH)2D3 by up-regulating the CYP24A1 gene, the GFAP gene 
was measured. RT-PCR was used to measure the effect of 1,25(OH)2D3 on 
GFAP mRNA levels. GFAP mRNA levels were found to be significantly less 
when treated with 1,25(OH)2D3 at a concentration of 1x10-10M (p=.047), but not 
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significantly different from controls when treated with higher concentrations, 
1x10-8M and 1x10-6M (p=.60 and p=.39) respectively. The fold induction was 
measured by the delta delta ct method and a t-test was used to compare the 
mean RQ Values; see fig. 9. 
  
Figure 9. GFAP Induction by 1,25(OH)2D3. GFAP mRNA in primary rat cortical astrocyte cells 
treated for 8 hours with increasing concentrations of 1,25(OH)2D3 was measured using RT-PCR. 
The fold induction is represented by the relative quantity (RQ) value relative to control. Treatment 
with 1x10-10 1,25(OH)2D3 had a significant* effect (p=.047), but at the other concentration results 
were insignificant.  
 
 The amount of 3H-thymidine incorporated over a 3 hour time period by 
treated and untreated cells was measured. Cells treated with 1x10-6M 
1,25(OH)2D3 for 24 hours incorporated significantly less 3H-thymidine than 
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control groups (p=.026). Cells treated with 1x10-10M and 1x10-8M failed to reach 
a level of significance (p=.17 and p=.27) when mean values were compared to 
control using a t-test. Despite the non-significant finding, a trend whereby 
increasing concentrations of 1,25(OH)2D3 were inversely related to 3H-thymidine 
incorporation was apparent; see fig. 10.  
 
 
Figure 10. 3H-Thymidine Incorporation. Incorporation of 3H-thymidine was measured in primary 
rat cortical astrocytes after 24 hours treatment with 1,25(OH)2D3 and 3 hours of incubation with 
3H-thymidine. A dose response was apparent whereby increasing concentrations of 1,25(OH)2D3 
treatment corresponded with a decrease in the mean 3H-thymidine counts per minute (CPM) at 
each concentration. Cells treated with a concentration of 1x10-6M 1,25(OH)2D3 incorporated 
significantly* less 3H-thymidine indicating decreased proliferation compared to control (p=.026). 
Error bars denote SEM. 
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Figure 11. Vehicle Control Treated Astrocyte Cells. Primary rat cortical astrocytes treated with 
vehicle control (100% ethanol) for 24 hours and immunostained for nuclei, GFAP, VDR, and 
oligodendrocytes (not present). DAPI (Blue) stained for cell nuclei. Anti-VDR (red) labeled for the 
VDR receptor. Anti-GFAP (green) labeled for glial fibrillary acidic protein indicating type I 
astrocyte cells. Importantly without its ligand 1,25(OH)2D3 VDR is present in the cytosol of the 
cells. 
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Figure 12. 1,25(OH)2D3 Treated Astrocyte Cell. Primary rat cortical astrocytes were treated with 
1,25(OH)2D3 for 24 hours and immunolabeled for nuclei, GFAP, VDR, and oligodendrocytes. 
DAPI (Blue) stained for cell nuclei. Anti-VDR (red) labeled for VDRs. Anti-GFAP (green) labeled 
for glia fibrillary acidic protein, indicating type I astrocyte cells. No oligodendrocytes were 
apparent in this section. A composite shows the magenta co-localization of the ligand, 
1,25(OH)2D3, bound VDR present predominantly in the nuclei of the cell. 
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Figure 13. 1α-Hydroxylase in Keratinocytes and Astrocytes. Anti-1α-hydroxylase (grey) labeled 
CYP27B1 and DAPI (blue) stained cell nuclei in human keratinocytes; column (a), and rat primary 
cortical astrocytes, column (b). Additionally, anti-GFAP (green) denoted astrocyte cells. 
Localization of CYP27B1 in keratinocyte cells appeared predominently perinuclear or nuclear 
whereas CYP27B1 in astrocyte cells appeared predominantly perinuclear or cytosolic. 
a b 
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DISCUSSION 
 
 This study investigated the effects of vitamin D on astrocytes by 
measuring 3H-thymidine incorporation and by measuring induction of GFAP 
mRNA in an astrocyte-enriched culture. For the 3H-thymidine incorporation 
experiments; treating cultured astrocytes with 1,25(OH)2D3 showed a dose 
dependent trend, and at 1x10-6M 1,25(OH)2D3 significantly (p<0.026) reduced 
3H-thymidine incorporation in the astrocytes compared to control, indicating that 
1,25(OH)2D3 has a role in reducing proliferation of astrocytes. These results are 
supported by previous evidence that 1,25(OH)2D3 affects cell cycle regulation in 
C6 glioma cell lines50. Longer incubation times with both the 1,25(OH)2D3 
treatment and 3H-thymidine would help further validate these findings, especially 
for lower concentrations that were not significant over the time periods used in 
this study. 
 When the study focused on VDR target genes short (6-8 hours) treatment 
times were used; whereas, when the focus was on cell proliferation longer (24 
hours) treatment times were used. Treatment times that range between 48 hours 
to one week may be more appropriate to measure 3H-thymidine incorporation in 
primary rat astrocytes because of their relatively slow growth as compared to 
cancer cell lines such as DU-145 prostate cancer cells. Thus, incubation times 
longer than those performed in this study should be considered in future 
experiments. Moreover, treatment with 25(OH)D3 may yield results similar to 
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those found by treating cells with 1,25(OH)2D3 and support that the astrocytes 
indeed have 1α-hydroxylase to locally activate 25(OH)D3. Additional studies 
would give valuable insight into these two questions:  whether 1α-hydroxylase is 
present in astrocytes and how the circulating form of vitamin D, 25(OH)D3, 
functions. 
 After measuring the effect of 1,25(OH)2D3 on cell proliferation, the study 
investigated effects of 1,25(OH)2D3 on specific genes including VDR, CYP24A1, 
CYP27B1, and GFAP. In the primary astrocyte culture the genomic regulatory 
pathways for 1,25(OH)2D3 were intact. 24-hydroxylase mRNA was up-regulated 
when cells were treated with concentrations of 1x10-6M (p<0.05) as expected and 
previously reported16. Similar findings have recently been reported in the brain 
tissue of MS (Multiple Sclerosis) patients whereby 24-hydroxylase mRNA 
up-regulation was specific to astrocytes60.  
 Unlike the 24-hydroxylase mRNA, the fold induction for 1α-hydroxylase 
mRNA could not be determined. RT-PCR for 1α-hydroxylase consistently had 
late detection calls indicating uncertainty that as to whether low levels of 
CYP27B1 mRNA was even present. In other samples CYP27B1 mRNA went 
undetected. Two possible explanations are that; mRNA for the CYP27B1 may 
not be present in astrocytes; or the primer/probe may not have specificity for the 
rat CYP27B1 mRNA sequence. Similarly, western blots indicated that the protein 
level for 1α-hydroxylase in astrocytes was low to non-existent compared with 
positive control transfected LNCap cells. This finding was not surprising and 
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indicates that astrocytes may rely on other cell types to activate 25(OH)D3; 
specifically microglial cells.  
 Astrocytes and microglia have different embryological origins, ectoderm 
and marrow monocyte precursors respectively, leading to the possibility that they 
have different roles concerning 1α-hydroxylase61. Rat microglia have been 
reported to activate 25(OH)D3 at concentrations of up to 5.8fmol 1,25(OH)2/8x105 
cells every 2 hours. In these same studies detection of 1,25(OH)2D3 in resting 
microglia was essentially undetectable until the microglia became active as 
macrophages, suggesting that once microglia become active, 1,25(OH)2D3 levels 
in the brain increase15.  
 The results from immunohistochemical labeling demonstrated 
1α-hydroxylase was present in astrocytes, which provided better sensitivity than 
RT-PCR or western blot analysis. Recent studies on brains from MS patients 
have demonstrated induction of CYP27B1 by 1,25(OH)2D3 in human astrocytes, 
but effects in these studies may not be directly attributed to 1,25(OH)2D3 but 
rather are secondary effects of TNF-α (see table 1. for TNF-α and 
1,25(OH)2D3)60. Thus, further experiments are required to determine effects of 
1,25(OH)2D3 on 1α-hydroxylase mRNA and protein production by primary rat 
cortical astrocytes in vitro. 
 The mixed findings pertaining to 1α-hydroxylase beg an examination of 
the physiology of astrocytes. In vivo, astrocytes may rely on circulating 25(OH)D3 
which, along with 1,25(OH)2D3—appears to cross the blood brain barrier where, if 
  
 
35 
25(OH)D3 is not already activated, can be activated locally11,56. In order to 
understand signaling between cells that use 1,25(OH)2D3, it is important to 
understand which specific cell type is activating 25(OH)D3 by producing 
1α-hydroxylase. The experiments in this study; however, focused only on treating 
astrocytes directly with active 1,25(OH)2D3. Future investigators should be aware 
that other groups have reported similar difficulties investigating 1α-hydroxylase. 
Eyles, Burne, and McGrath report that they have opted to develop their own 
primers and antibodies to detect the gene and protein, and they caution against 
the use of polyclonal antiserums when investigating 1α-hydroxylase or even 
VDR, as suggested by Wang and DeLuca62,63. 
 To determine whether 1α-hydroxylase is indeed produced by astrocytes, 
the following experiments could be conducted: First, co-localizating 
1α-hydroxylase with mitochondria would help validate immunolabeling. Second, 
performing western blots using keratinocytes or even transfected keratinocytes 
as a positive control would eliminate confounders caused by transfecting a 
1α-hydroxylase negative cell line, LnCAP cells in this experiment, with 
1α-hydroxylase.64 LnCAP cells, however, appear adequate as a negative 
control65,66. Third, investigating the metabolism of 3H-25(OH)D3 to 
3H-1,25(OH)2D3 would confirm activation of 3H-25(OH)D3 in vitro. 
 To date, no study to this investigators knowledge has determined the 
concentration of 25(OH)D3 in the brain or whether brain levels of 25(OH)D3 
metabolites are similar to levels found in other body tissues. Further research 
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into 25(OH)D3 and 1,25(OH)2D3 concentrations will have important implications 
for studying effects of 1,25(OH)2D3 in the brain, since genomic effects may 
depend on the brain concentrations of 1,25(OH)2D3 and 25(OH)D3; see fig. 9. 
Determining the approximate concentrations of 25(OH)D3 and 1,25(OH)2D3 in the 
brain in vivo could help guide in vitro experiments and better translate results to 
clinical applications. Regardless, this study did confirm what prior studies have 
shown:  that the VDR receptor is present and that when cells are treated with the 
ligand 1,25(OH)2D3 the VDR translocates into the nucleus and exerts its genomic 
effect by up-regulating 24-hydroxylase. 
 GFAP is well known as a marker in one of two types of astrocytes and has 
been described as a marker of differentiation under developmental and 
pathological conditions67,68. Therefore, although the 3H-thymidine incorporation 
study showed that cell proliferation was decreased; cell differentiation may also 
be reduced by 1,25(OH)2D3 at one concentration or less likely, induced at 
another concentration in astrocytes. Results from RT-PCR experiments on four 
separate primary rat cortical astrocyte cultures revealed that GFAP mRNA was 
down-regulated at a physiological concentration of 1x10-10M but not affected at 
1x10-8M and 1x10-6M. These finding require further RT-PCR experiments to 
replicate the finding from the four independent culture samples. Non-qualitative 
imaging—and western blotting—may help answer whether 1,25(OH)2D3 affects 
GFAP at the protein level and help elucidate differences for the number of cells 
induced to differentiate between control and treated cultures.  
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 Reactive astrocytes responding to anoxic injury, traumatic brain injury, or 
acute head trauma have perplexed scientists and clinicians for some time. One 
popular viewpoint is that glial scaring, consisting of microglia/macrophages, 
extracellular matrix molecules including chondroitin sulfate proteoglycans 
(CSPG’s), and astrocytes, causes secondary degeneration and reduces the 
ability of neurons to regenerate. Scientists approach reducing secondary 
degeneration by targeting the proteoglycans that are produced primarily by 
astrocytes69. In some studies enzymatic targeting of these proteglycans improves 
neurite outgrowth70. Other approaches that aim to reduce secondary 
degeneration have focused on inhibiting astrocyte proliferation to reduce 
scaring71. In both approaches, the scar has been viewed as detrimental. 
 Another viewpoint; however, posits that there are both advantages and 
disadvantages to glial scar formation. In this view, the glial scar helps contain the 
injury and prevents macrophages from spilling outside the injury site and 
damaging other areas. Some scientists are attempting to treat the glial scaring 
with more sensitivity to temporal development of the scar by targeting specific 
goals at specific times. This approach seeks to take advantage of glial scarring’s 
containment possibilities but still maximizes neural growth factors72. 1,25(OH)2D3 
is a key player in cell proliferation, differentiation, inflammation, and even nerve 
regeneration; see table 1. The multifaceted genomic effects of 1,25(OH)2D3 relate 
to glial scar formation because astrocytes, which respond to 1,25(OH)2D3, play 
roles in the different stages of recovery from CNS damage. One of the problems 
  
 
38 
with brain damage is that regeneration cannot occur because astrocytes block 
pathways for neurons and outgrowth. 1,25(OH)2D3 may provide a means by 
which the adaptive injury response can be enhanced by controlling the glial scar.  
The inductive effects of 1,25(OH)2D3 on genes that modulate astrocytic function 
is fertile territory for future study.  
 One Billion people worldwide are believed to be either vitamin D 
insufficient or defcient73. The popular view of 1,25(OH)2D3 as a vitamin related 
only to calcium homeostasis distracts from the importance of 1,25(OH)2D3 as a 
hormone in other tissues. The role of vitamin D extends beyond bone health and 
preventing extreme deficiency symptoms like rickets. This experiment confirmed 
previous findings using primary rat cortical astrocytes and set some ground for 
these experiments to be replicated, improved upon, and advanced. Moreover, 
genes that affect formation of glial scars may help mediate critical time points 
and goals for recovery such as; containing the injury, reducing inflammation, and 
initiating nerve growth or repair in response to injury. With the prevalence of 
vitamin D deficiency in the general population, one is left to wonder what both the 
short term and long term affects of recovery from brain injury might be if vitamin 
D status were improved. While astrocytes represent the largest number of cells in 
the CNS; they are only one of many, but there are few better places to explore 
vitamin D beyond bone and into the brain.  
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